[ad_1]
Johnson & Johnson announced that it had reached full recruitment for its single-dose, advanced coronavirus vaccine trial with around 45,000 participants.
In a statement from the company, the health giant said there is a high incidence of the virus circulating among the general population where US-based study trials (called Ensemble) are underway, which will allow the business to get the data it needs. In general, when the disease rate decreases in a population, it can slow down the enrollment process.
WHO SHOULD REACH COVID-19 VACCINES?
Company officials have said that provisional data, or data released before the trial is complete, is expected by the end of January 2021. Although this news lags behind other companies on the COVID-19 vaccine front, like Pfizer and Moderna, officials are welcoming as many vaccine candidates as possible in order to meet global demand and, ultimately, overcome the current health crisis.
GET THE FOX NEWS APP
If the data suggests the vaccine is safe and effective, Johnson & Johnson said they plan to file for emergency approval with the United States Food and Drug Administration in February. The company said a second trial was working to explore another COVID-19 vaccine candidate with a two-dose regimen.
The company had suspended its trial for more than a week in mid-October due to “unexplained illness” in a trial participant, but resumed trials after an evaluation failed to identify any clear cause. The company later announced that it “found no evidence that the vaccine candidate caused the event.”
[ad_2]
Source link